Equity Profile

SUPN

Supernus Pharmaceuticals, Inc.

Health CarePharmaceuticals$2.6B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for central nervous system diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract more customers, which is crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SUPN Q2-2026 Earnings Preview

Context

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for central nervous system diseases. With a market cap of $3 billion, it plays a significant role in the pharmaceuticals sector, particularly in addressing unmet medical needs in neurology and psychiatry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-78.10%

Avg Stock Reaction

+1.56%

Last Quarter Recap

In Q1-2026, Supernus reported an EPS of -$0.04, significantly missing the expected $0.14. Despite this disappointing result, the stock saw a slight increase of 1.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Supernus are cautious given the recent earnings misses, but there is hope for recovery if the company can show improvement in its product pipeline and financial metrics.

Bull Case

If Supernus can demonstrate a turnaround in earnings and provide positive updates on its drug pipeline, investor confidence could rebound, leading to a significant stock price increase.

Bear Case

Continued earnings misses or lack of progress in product development could lead to further declines in stock price, as investors may lose faith in the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for the product pipeline and any upcoming clinical trial results?

Investors will closely watch for any signs of progress that could impact future revenue and growth.

How does management plan to address the recent earnings misses and improve profitability?

Clear strategies for financial recovery will be crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in Supernus's product pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

Recent insider buying suggests confidence in the company's future prospects.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

The company's historical performance shows that even after misses, there can be rebounds if management provides strong guidance.

Key Risk

If the product pipeline shows significant advancements or positive trial results, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Supernus can turn around its recent performance and regain investor trust.

Bull Confirmed If

A return to positive EPS, ideally above $0.10, would confirm the bull case.

Bear Confirmed If

An EPS of -$0.10 or worse would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.16%

Historical Avg

±1.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±19.2% while SUPN has averaged ±1.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.3%

Calls (300)P/C Ratio: 0.67Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Supernus beats expectations, history suggests a potential stock increase of around 1.10%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, reflecting ongoing investor caution.

Miss

If the company misses again, history suggests a potential decline of around 1.83%, further eroding investor confidence.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for upcoming clinical trials.
2Management's strategy for addressing recent earnings misses.
3Details on revenue growth expectations for the upcoming quarters.
4Insights into the competitive landscape and how Supernus plans to differentiate its products.
5Any commentary on potential partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for central nervous system diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract more customers, which is crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SUPN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-78.10%

Avg Stock Reaction

+1.56%

Last Quarter Recap

In Q1-2026, Supernus reported an EPS of -$0.04, significantly missing the expected $0.14. Despite this disappointing result, the stock saw a slight increase of 1.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Supernus are cautious given the recent earnings misses, but there is hope for recovery if the company can show improvement in its product pipeline and financial metrics.

Bull Case

If Supernus can demonstrate a turnaround in earnings and provide positive updates on its drug pipeline, investor confidence could rebound, leading to a significant stock price increase.

Bear Case

Continued earnings misses or lack of progress in product development could lead to further declines in stock price, as investors may lose faith in the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for the product pipeline and any upcoming clinical trial results?

Investors will closely watch for any signs of progress that could impact future revenue and growth.

How does management plan to address the recent earnings misses and improve profitability?

Clear strategies for financial recovery will be crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in Supernus's product pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

Recent insider buying suggests confidence in the company's future prospects.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

The company's historical performance shows that even after misses, there can be rebounds if management provides strong guidance.

Key Risk

If the product pipeline shows significant advancements or positive trial results, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Supernus can turn around its recent performance and regain investor trust.

Bull Confirmed If

A return to positive EPS, ideally above $0.10, would confirm the bull case.

Bear Confirmed If

An EPS of -$0.10 or worse would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.16%

Historical Avg

±1.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±19.2% while SUPN has averaged ±1.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.3%

Calls (300)P/C Ratio: 0.67Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Supernus beats expectations, history suggests a potential stock increase of around 1.10%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, reflecting ongoing investor caution.

Miss

If the company misses again, history suggests a potential decline of around 1.83%, further eroding investor confidence.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for upcoming clinical trials.
2Management's strategy for addressing recent earnings misses.
3Details on revenue growth expectations for the upcoming quarters.
4Insights into the competitive landscape and how Supernus plans to differentiate its products.
5Any commentary on potential partnerships or collaborations that could enhance growth.